Lipid-Lipoprotein and Oxidative Stress Markers in Patients with Metabolic Syndrome

CLINICAL RESEARCH
Nelly R. Uzbekova

Andijan State Medical Institute; Andijan, Uzbekistan

*Corresponding author: Nelly R. Uzbekova. Andijan State Medical Institute. Andijan, Uzbekistan. E-mail: tursunov1@yandex.com

Published: March 25, 2014.

Abstract: 

The lipid-lipoprotein and oxidative stress markers in the different levels of glucose-insulin homeostasis have been studied in patients with metabolic syndrome (MS). The increase in the levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), as well as the decrease in High-Density Lipoprotein Cholesterol (HDL-C) was revealed to be one of the causes of hyperinsulinemia and insulin resistance (IR). Increased lipolysis activates the oxidative stress (OS). The leading role of TG as an indicator of high atherogenic potential of plasma in MS has been determined.

Keywords: 
lipoproteins; oxidative stress; metabolic syndrome.
References: 
  1. Chazova IE, MichkoVB. Metabolic syndrome. Handbook. Moscow: Media- Medika; 2008.
  2. Conti CR. The metabolic syndrome: is it realty a syndrome? Clin Cardiol 2006; 29(12):523-4.
  3. Antonyuk MV, Knishova VV. The role of lipid abnormalities in the formation of the metabolic syndrome. Ross Kardiol J 2011:5:30-34.
  4. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes and cardiovascular diseases:executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28(1):88-136.
  5. Oda E. The metabolic syndrome as a concept of adipose tissue disease. Hypertens Res 2008; 31(7):1283-91.
  6. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005;112(17):2735-52.
  7. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107(3):499-511.
  8. Steinberg D. Hypercholesterinemia and inflammation in atherogenesis: two sides of the same coin. Mol Nutr Food Res 2005; 49(11):995-8.
  9. Stocker R, Keaney JFJr. New insights on oxidative stress in the artery wall. J Thromb Haemost 2005; 3(8):1825-34.
  10. Shankar SS, Steinberg HO. FFAs: do they play a role in vascular disease in the insulin resistance syndrome? Curr Diab Rep 2005;5(1):30-5.
  11. Reaven GM. The individual components of the metabolic syndrome: is there a raison d’etre? J Am Coll Nutr 2007; 26(3):191-5.
  12. Tabet F, Rye KA. High-density lipoproteins, inflammation and oxidative stress. Clin Sci (Lond) 2009; 116(2):87-98.
  13. Nitenberg A, Cosson E, Pham I. Postprandial endothelial dysfunction: role of glucose, lipids and insulin. Diabetes Metab 2006; 32(2):2S28-33.

The fully formatted PDF version is available.

Download Article

Int J Biomed. 2014; 4(1):19-22. © 2014 International Medical Research and Development Corporation. All rights reserved.